新闻

Browse 493 market data Tables and 50 Figures spread through 550 Pages and in-depth TOC on "Cancer Biomarkers Market - Global Forecast to 2032" Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=202 The growth in the market will primarily be attributed to the use of biomarkers in oncological treatment approaches, along with rising cancer rates worldwide. Other factors that have led to the substantial growth of the cancer biomarkers market include the use of precision medicines and innovative methods for identifying biomarkers through genomics, proteomics, and multi-omics. Despite all the above-mentioned positive factors, there are certain limitations within the market. High costs required to perform complex diagnostic procedures, such as next-generation sequencing and multi-omics, pose an obstacle to their more frequent use, especially in developing countries. Moreover, issues with insurance coverage are another obstacle that prevents many patients from receiving biomarker-based diagnostics. Issues such as variability in sampling and processing also need to be considered when considering these tests. In the cancer biomarkers market, the omics technology segment accounted for the largest share within the profiling technology segment in 2026. The market for cancer biomarkers has been divided into two segments based on profiling methods: omics technologies and imaging technologies. As of 2025, the cancer biomarkers market was dominated by the omics technology segment, mainly due to the high-throughput nature of these technologies in cancer biomarker discovery and diagnosis. Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=202 In the cancer biomarkers market, the breast cancer segment accounted for the largest share within the cancer type segment in 2026. The market for cancer biomarkers is divided into categories by cancer type: non-Hodgkin lymphoma, kidney cancer, bladder cancer, thyroid cancer, breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, leukemia, and other cancer types. In 2025, the market for cancer biomarkers was dominated by the breast cancer segment. The huge share of this segment is due to the growing rate of breast cancer cases worldwide, followed by awareness for diagnosis, prevention, and treatment. North America dominated the cancer biomarkers market in 2026. The cancer biomarkers market is segmented into six regions: Asia Pacific, Latin America, North America, Europe, the Middle East & Africa, and GCC Countries. North America held the largest market share in the cancer biomarkers market in 2026. The market in this region is growing due to its healthcare infrastructure, high cancer incidence, and increased number of diagnostic tests performed. High demand for cancer biomarkers in this region is driven by the presence of high-end diagnostic centers and hospitals, along with stringent regulatory requirements for diagnostic accuracy, quality, and early disease detection. Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=202 Top Companies in Cancer Biomarkers Market: The Top Companies in Cancer Biomarkers Market include Thermo Fisher (US), Roche Hoffmann (Switzerland), Illumina (US), Quest Diagnostics (US), and Agilent Technologies (US). MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. MarketsandMarkets™ SalesPlay is an AI-driven Revenue Intelligence Co-Pilot designed to help revenue teams prioritize the right accounts, identify critical changes early, and surface opportunities ahead of demand, so pipeline builds naturally and deals close with greater consistency. View original content:https://www.prnewswire.co.uk/news-releases/cancer-biomarkers-market-worth-54-48-billion-by-2032-marketsandmarkets-302774472.html

In a groundbreaking advancement for cancer treatment, researchers at The University of Texas MD Anderson Cancer Center have unveiled transformative findings that could reshape how clinicians approach the management of early metastatic cancers. Leveraging the power of circulating tumor DNA (ctDNA) testing, the Phase 2 EXTEND trial delivered compelling evidence that this non-invasive biomarker significantly outperforms traditional lesion-counting methods in assessing treatment response for patients undergoing metastasis-directed therapy (MDT). Historically, oncologists have relied on medical imaging to quantify the number and size of cancer lesions, guiding decisions about the potential benefit of localized interventions such as radiation therapy. While effective to a degree, this approach suffers from limitations in sensitivity and reproducibility, often failing to capture microscopic disease or providing a clear real-time indication of therapeutic efficacy. The EXTEND trial confronts these challenges head-on by integrating ctDNA analysis, which detects fragments of tumor-derived DNA circulating freely in the bloodstream, offering a dynamic molecular snapshot of tumor burden and disease activity. Under the leadership of Chad Tang, M.D., Associate Professor of Genitourinary Radiation Oncology, the EXTEND trial included meticulous collection of blood samples at baseline and after three months of therapy. These time points allowed researchers to track fluctuations in ctDNA, correlating molecular signals with clinical outcomes. Remarkably, patients with detectable ctDNA at enrollment exhibited a higher likelihood of disease progression, underscoring the prognostic value of this biomarker. Conversely, a reduction in ctDNA levels following MDT correlated strongly with favorable treatment responses, signaling the molecular eradication of metastatic clones. This molecular insight offers distinct advantages over radiologic assessments. Tumors releasing persistent ctDNA despite localized treatment frequently indicated hidden or aggressive disease that might not yet be visible on scans. Such early warnings provide oncologists with a critical window to adapt therapeutic strategies swiftly -- escalating or modifying treatment regimens before macroscopic progression occurs. In this way, ctDNA serves as a sensitive barometer of cancer dynamics, empowering a more personalized and precise oncologic approach. Beyond patient monitoring, the study highlights the broader implications for the clinical adoption of MDT, particularly in oligometastatic prostate cancer, where the metastasis-directed approach is evolving into a new standard of care. By harmonizing ctDNA testing with established imaging techniques, clinicians gain a multifaceted toolkit to delineate metastatic spread with unprecedented accuracy. This dual-modality strategy enhances staging precision and refines radiation targeting, ultimately improving patient prognoses and minimizing collateral tissue damage. Alex Sherry, a former resident at MD Anderson and current investigator at Mayo Clinic, spearheaded the statistical analyses underpinning these conclusions. His work validated the robustness of ctDNA as an adjunctive measure that complements, rather than replaces, conventional imaging. This innovative framework bridges molecular oncology and radiotherapy, crystallizing a future in which dynamic biomarkers inform real-time, adaptive treatment decisions. The EXTEND trial's promising results also illuminate biological complexities underpinning metastatic progression. Persistent ctDNA post-MDT may herald tumor heterogeneity and emerging resistance phenotypes that thwart localized therapy. Recognizing these molecular hallmarks can direct research toward novel systemic agents that synergize with radiation, fostering durable remissions even in the face of biologically aggressive disease. Furthermore, the trial exemplifies the growing shift towards minimally invasive diagnostics in oncology. Blood-based assays such as ctDNA testing circumvent the risks associated with serial biopsies while offering scalable and reproducible measures of tumor burden. This technological evolution is poised to revolutionize clinical workflows and patient experience, facilitating more frequent and accessible monitoring without compromising accuracy. This research was bolstered by prominent funding from the Cancer Prevention and Research Institute of Texas (CPRIT) and the National Cancer Institute (NCI), with Guardant Health providing the ctDNA testing platform. Rigorous methodological standards and transparent disclosures accompany the published findings in the Journal of Clinical Oncology, reinforcing the credibility of this landmark study. The implications of these findings extend beyond the trial's immediate scope, promising profound impact across diverse cancer types where metastatic dissemination remains a major therapeutic hurdle. As ctDNA assays become increasingly refined and integrated into clinical practice, they herald a paradigm shift from static imaging toward dynamic molecular surveillance, ushering in a new era of precision oncology. In sum, the EXTEND trial offers compelling evidence that circulating tumor DNA testing can revolutionize the management of oligometastatic cancers by providing a molecularly informed, real-time measure of treatment response. This innovation not only sharpens prognostication but also enhances therapeutic agility, laying the groundwork for improved patient outcomes in the complex battle against metastatic disease. References: Tang C, et al. Phase 2 EXTEND trial. Journal of Clinical Oncology. DOI: 10.1200/JCO-25-02856. Image Credits: The University of Texas MD Anderson Cancer Center Keywords: Radiation therapy, circulating tumor DNA, ctDNA, metastasis-directed therapy, MDT, oligometastatic cancer, prostate cancer, molecular oncology, precision medicine, tumor biomarkers